Clinical trials: Metastatic Renal Cancer
Kidney Cancer
Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00003683
- Testing
- doxorubicin hydrochloride, ifosfamide
- Where
- 14 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Metastatic Renal Cell Carcinoma
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether the experimental vaccine G250 with or without IL-2 can produce an immune response in patients with renal cell carcinoma who have had all their cancer removed by surgery.
- Trial name
- NCT00203866
- Testing
- G250 peptide, IL-2
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Chicago
Metastatic Renal Cell Carcinoma
Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb
This is a prospective, single-arm, monocentric translational study designed to evaluate possible biomarkers of resistance to the first line of therapy with pazopanib in patients with metastatic renal cell carcinoma (mRCC) who…
- Trial name
- PIPELINE (NCT04462445)
- Testing
- Pazopanib
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
This phase II trial investigates the side effects of tocilizumab, ipilimumab, and nivolumab in treating patients with melanoma, non-small cell lung cancer, or urothelial carcinoma that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma
- Trial name
- NCT04940299
- Testing
- Ipilimumab, Nivolumab, Tocilizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Ewing Sarcoma, Rhabdomyosarcoma
Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
This research study is studying stereotactic body radiotherapy (SBRT) as a possible treatment for lung relapse of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other…
- Conditions
- Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Osteosarcoma
- Trial name
- NCT02581384
- Testing
- Stereotactic Body Radiotherapy (SBRT)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Melanoma, Advanced Locoregional Melanoma
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma.
- Conditions
- Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
- Trial name
- NCT05155033
- Testing
- Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma
Everolimus indirectly inhibits angiogenesis by reducing VEGF production. VEGF can be non-invasively visualized and quantified with serial 89Zr-bevacizumab PET imaging in patients.
- Trial name
- Everolimage (NCT01028638)
- Testing
- 89Zr-bevacizumab PET scan
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- University Medical Center Groningen
Renal Cell Carcinoma (RCC)
To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer
This is a single-arm, open-label, dose-escalating Phase 1 clinical study. It aims to evaluate the safety, tolerability and pharmacokinetic(PK) profiles of the investigational agent, and preliminarily assess its efficacy in…
- Trial name
- NCT07647744
- Testing
- Anti-Human CD70 T-Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022633
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 92 sites in United States
- Volunteers
- 65 people
- Sponsor
- SWOG Cancer Research Network
Kidney Neoplasms
The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer
The primary objective of this study is to determine the percentage of patients with a plasma concentration of sunitinib remaining at equilibrium ([Suni]REq) greater than 100 ng / ml (effective concentration according to the…
- Trial name
- GenCInibs-Suni (NCT02404584)
- Testing
- Blood drawn for genotyping, Blood drawn for pharmacokinetic measures
- Where
- 3 sites in France
- Volunteers
- 43 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Advanced Solid Tumors, Metastatic Breast Cancer
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Study has two parts: 1. Dose-finding: to determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of RAD001 (everolimus , Afinitor®) in combination with BEZ235 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
- Trial name
- NCT01482156
- Testing
- RAD001 + BEZ235
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.
- Trial name
- NCT00586105
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 8 sites in China, Taiwan
- Volunteers
- 39 people
- Sponsor
- Bayer
Neoadjuvant Therapy, Advanced Cancer
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of toripalimab combined with axitinib as neoadjuvant therapy for advanced/metastatic non-clear cell renal cell carcinoma
- Conditions
- Neoadjuvant Therapy, Advanced Cancer, Metastatic Kidney Cancer
- Trial name
- NCT04385654
- Testing
- Toripalimab, Axitinib
- Volunteers
- 40 people
- Sponsor
- West China Hospital
Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
This study is testing whether adding a 5-day fasting-mimicking diet (FMD) can help people with advanced kidney cancer when given together with standard first-line cancer medicines.
- Conditions
- Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
- Trial name
- NCT07500831
- Testing
- Fasting mimicking diet, Toripalimab, Axitinib
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Qilu Hospital of Shandong University
Carcinoma, Renal Cell
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.
- Trial name
- NCT02454478
- Testing
- Lenvatinib, Everolimus
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Eisai Co., Ltd.
Advanced Renal Cell Carcinoma
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (PFS) and evaluate the safety and tolerability of AMG 386 in combination with sorafenib…
- Trial name
- NCT00467025
- Testing
- AMG 386, Sorafenib
- Volunteers
- 152 people
- Sponsor
- Amgen
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
This phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT05092958
- Testing
- Avelumab, Biospecimen Collection, Bone Scan
- Where
- 275 sites in United States, Canada
- Volunteers
- 654 people
- Sponsor
- National Cancer Institute (NCI)
Clear-cell Metastatic Renal Cell Carcinoma
Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
The purpose of this study is to assess whether certain metabonomics and/or lipidomics features in correlation with pharmacokinetics before, during and after treatment with sunitinib or pazopanib in first line can predict toxicity…
- Trial name
- METASUN (NCT02570789)
- Testing
- patients with sunitinib or pazopanib
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Advanced Clear Cell Renal Cell Carcinoma
Avelumab, Palbociclib and Axitinib in Advanced RCC
The aim of this study is to see whether the combination of 3 drugs (axitinib, avelumab and palbociclib) is safe and effective in slowing down the growth of advanced clear cell renal cell carcinoma (ccRCC) in patients that have…
- Trial name
- APART (NCT05176288)
- Testing
- Axitinib, Palbociclib, Avelumab
- Sponsor
- Bradley A. McGregor, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.